2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-12413A
    BMS-986118 1610562-74-7 98%
    BMS-986118 is a potent, orally active, and selective GPR40 agonist with an EC50 of 0.07 µM. BMS-986118 has dual insulinotropic and GLP-1 secretory effects, resulting in robust plasma glucose lowering effects in acute animal models.
    BMS-986118
  • HY-124178
    (R)-Levrazoxane 24613-06-7 98%
    (R)-Levrazoxane ((R)-ICRF 186) is enzymatically hydrolysed to one-ring open intermediates by dihydropyrimidine amidohydrolase (DPHase), which is present in the liver and kidney. The radiosensitizing efficiency of (R)-Levrazoxane towards EMT6 mouse mammary tumour cells is greater than that of Dexrazoxane (HY-B0581). (R)-Levrazoxane is promising for research of liver and kidney related diseases.
    (R)-Levrazoxane
  • HY-124303
    4(Z),7(Z),10(Z),13(Z),16(Z)-Nonadecapentaenoic acid 136156-13-3 98%
    4(Z),7(Z),10(Z),13(Z),16(Z)-Nonadecapentaenoic acid is a polyunsaturated fatty acid (PUFA).
    4(Z),7(Z),10(Z),13(Z),16(Z)-Nonadecapentaenoic acid
  • HY-12433A
    BMS-830216 1197420-06-6 98%
    BMS-830216 is an antagonist of MCHR-1. BMS-830216 is a phosphate ester prodrug. BMS-830216 can be studied in obesity-related research.
    BMS-830216
  • HY-124364
    RO6889678 1578153-27-1 98%
    RO6889678 is a highly potent HBV capsid formation inhibitor with a complex absorption, distribution, metabolism, and excretion (ADME) profile. RO6889678 is a potent inducer of CYP3A4 and coregulated proteins in human hepatocytes. RO6889678 is metabolized by a combination of CYP3A4-mediated oxidation and UDP-glucuronosyltransferase UGT1A3- and UGT1A1-mediated direct glucuronidation.
    RO6889678
  • HY-124374
    J-104123 162037-54-9 98%
    J-104123 is an inhibitor of squalene synthase with monocarboxylic acid structure. J-104123 can lower serum cholesterol level in dog models.
    J-104123
  • HY-124396
    Lanceotoxin A 93771-82-5 98%
    Lanceotoxin A is a potent potassium channel inhibitor with activity in regulating cell membrane potential. Lanceotoxin A showed a significant negative correlation with extracellular metabolites in patients after metabolic surgery. The presence of lanceotoxin A may affect the composition of intestinal microorganisms and its association with insulin resistance. Lanceotoxin A may play an important role in the improvement of metabolic syndrome and diabetes.
    Lanceotoxin A
  • HY-124420
    MLS-0322825 853310-63-1 98%
    MLS-0322825 is a selective low molecular weight protein tyrosine phosphatase (LMPTP) inhibitor with an IC50 of 3.3 μM for LMPTP-A. MLS-0322825 shows exquisite selectivity over other phosphatases (class I tyrosine-specific lymphoid phosphatase (LYP) and class I dual-specific vaccinia H1-related phosphatase (VHR)). MLS-0322825 can be used for the research of type 2 diabetes[1].
    MLS-0322825
  • HY-124446
    Dibromsalicil 523-88-6 98%
    Dibromsalicil (Compound 31) is a carboxylesterase (CES) inhibitor with activity of 72.7 nM against hiCE (human intestinal carboxylesterase) and 53.5 nM against rCE (rabbit liver carboxylesterase). Dibromsalicil has almost no activity against hCE1 (human liver carboxylesterase) and cholinesterase.
    Dibromsalicil
  • HY-124487
    GK-136901 1062624-71-8 98%
    GK-136901 is an orally active, dual Nox1/Nox4 NADPH oxidase inhibitor with a Ki of 160 nM for Nox1 and 165 nM for Nox4. GK-136901 potently blocks high glucose-induced intracellular reactive oxygen species production, p38-MAPK phosphorylation, and upregulation of TGF-β1/2 and fibronectin (fibronectin) in renal cells. GK-136901 also inhibits the proliferation of mouse pulmonary vascular cells under hypoxic conditions. GK-136901 is applicable to the research on the pathogenesis of type 2 diabetic nephropathy, high glucose-related renal lesions and pulmonary hypertension.
    GK-136901
  • HY-124557
    Mahanimbine 21104-28-9 98%
    Mahanimbine is an orally active alkaloid from Murraya koenigii. Mahanimbine inhibits progression of high-fat diet (HFD)-induced metabolic complications in mice.
    Mahanimbine
  • HY-124560
    Lifibrol 96609-16-4 98%
    Lifibrol is a potent and oral activity hypolipidemic agent. Lifibrol decreases the plasma total cholesterol. Lifibrol has the potential for the research of hypercholesterolemia.
    Lifibrol
  • HY-124581
    DS-6930 1242328-82-0 98%
    DS-6930 is a potent and selective agonist of PPARγ, with an EC50 of 41 nM. DS-6930 could robust reduce plasma glucose (PG), and with fewer PPARγ-related adverse effects than Rosiglitazone. DS-6930 can be used for the research of diabetes.
    DS-6930
  • HY-124661
    PF-06678419 2055468-48-7 98%
    PF-06678419 is a sodium-coupled citrate transporter and sodium-dependent dicarboxylate transporter inhibitor. PF-06678419 inhibits citrate uptake by interacting with residues near and outside NaCT’s citrate binding site. PF-06678419 can be used for the research of type 2 diabetes mellitus.
    PF-06678419
  • HY-124665
    LMP-420 473870-63-2 98%
    LMP-420 is a selective tumor necrosis factor-α (TNF-α) inhibitor. LMP-420 reduces the release of pro-inflammatory cytokines (e.g., IL-1β, IL-2), inducing the expression of anti-inflammatory cytokine IL-10 and anti-apoptotic molecules SOCS-1 and Mn-SOD. LMP-420 also downregulates chemokines (e.g., IP-10, MCP-1) to reduce immune cell infiltration. LMP-420 is promising for research of type 1 diabetes mellitus, inflammatory diseases (e.g., colitis), and HIV-Mycobacterium tuberculosis coinfection.
    LMP-420
  • HY-124779
    (S)-Alaproclate 66171-75-3 98%
    (S)-Alaproclate ((S)-GEA 654) is more potent than the R-(+)-enantiomer both in blocking the NMDA receptor currents in vitro and in antagonizing the cGMP increase in vivo.
    (S)-Alaproclate
  • HY-124919
    JJO-1 16722-44-4 98%
    JJO-1 is an AMPK activator with an EC50 of 1.8 μM. JJO-1 can be used in the study of obesity and type 2 diabetes.
    JJO-1
  • HY-124978
    MK-8282 1147556-27-1 98%
    MK-8282 is a potent, orally active GPR-119 agonist. MK-8282 shows improved glucose tolerance. MK-8282 can be used in the research of type 2 diabetes.
    MK-8282
  • HY-12525B
    LGD 6972 ammonium
    LGD-6972 ammonium is a selective and orally active glucagon receptor antagonist. LGD-6972 ammonium has the potential for type 2 diabetes research.
    LGD 6972 ammonium
  • HY-125265
    JTP-117968 2250132-99-9 98%
    JTP-117968, a novel selective glucocorticoid receptor modulator (a non-steroidal SGRM, IC50 of 6.8 nM), exhibits improved transrepression/transactivation dissociation.
    JTP-117968
Cat. No. Product Name / Synonyms Application Reactivity